Orchestra BioMed
OBIO | NASDAQ
$7.12
-$0.13 (-1.79%)
At close: Nov 16, 2026, 4:00 PM ET
$7.12
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-1.79%
(1D)No price chart data available for 1D timeframe.
Rating
54.5
-1.0 ptsFundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #196/1021 (Top 19%)
Key Statistics
Market Data
Market Cap $560.38M
1D Range
7.04 7.45
52W Range
3.49 7.45
Valuation (TTM)
PE -8
PB 29.89
EV/EBITDA -10.13
Valuation (NTM)
Forward PE N/A
Forward PEG 0.39
Price Target $10.00
Cash Flow
FCF Yield -11.4%
SBC Adj. FCF Yield -13.3%
SBC Impact -16.2%
Margins
Gross Margin 99.4%
Operating Margin -195.4%
FCF Margin -205.7%
Growth (CAGR)
Revenue 3Y | 5Y 105.4% |
79.6%
Dil EPS 3Y | 5Y 24.8% |
1.0%
FCF 3Y | 5Y -13.9% |
-18.7%
Returns
ROA -52.9%
ROE -140.2%
ROIC -64.6%
Financial Health
Net Cash
$29.5M
Current Ratio 7.25
Interest Coverage -15.07
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypert...
Sector Healthcare
Industry Biotechnology
Employees 86
IPO Date Aug 4, 2020
Website orchestrabiomed.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$0.3
Beat +25.14%
YoY:
+25.00% REV
$91K
Miss -29.69%
YoY:
-89.43%Next Earnings
Mar 11, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
6
Consensus
Buy
Price Target
$10.00
Upside
+40.45%
Buy (6)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove OBIO